1. Kyoizumi S, K Yoshiko, Kajimura J, Yoshida K, Imai K, Hayashi T, Nakachi K, Young LF, Moore MA, van den Brink MRM, Kusunoki Y. Age-associated changes in the differentiation potentials of human circulating hematopoietic progenitors to T- or NK-lineage cells. Journal of Immunology. 2013 (Epub ahead of print). 

  2. Ghosh A, Dogan Y, Moroz M, Holland AM, Yim N, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, Tsai JJ, Jenq RR, Penack O, Hanash AM, Smith   M, Piersanti K, Lezcano C, Murphy GF, Liu C, Palomba L, Sauer M, Sadelain M, Ponomarev V, van den Brink MRM. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. Journal of Clinical Investigation. 2013 (Epub ahead of print). (commentary in J Clin Invest. 2013; Epub ahead of print).

  3. Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, Hanash AM, Jakubowski A, Jenq R, Papadopoulos EB, Perales MA, van den Brink MRM, Young JW, Boulad F, O’Reilly RJ, Prockop S, Small TN, Scaradavou A, Kernan NA, Stevens CE, Barker JN. Graft-versus-host Disease After Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit Recipient HLA-match. Biology of Blood and Marrow Transplantation. 2013 (Epub ahead of print).

  4. Tsai JJ, Takahashi K, Dudakov JA, Shieh J, Singer NV, West ML, Smith OM, Young LF, Holland AM, Shono Y, Ghosh A, Tran HT, Moore MAS, van den Brink MRM. Nrf2 regulates haematopoietic stem cell function. Nature Cell Biology. 2013; 15(3): 309-16.

  5. Ubeda C, Bucci V, Caballero S, Djukovic A, Toussaint NC, Equinda M, Lipuma L, Ling L, Gobourne A, No D, Taur Y, Jenq R, van den Brink MRM, Xavier J, Pamer EG. Intestinal microbiota containing Barnesiella cures vancomycin-resistant Enterococcus faecium colonization. Infection and Immunity. 2013 (Epub ahead of print). 
  6. Hartrampf S, Dudakov JA, Johnson LK, Smith OM, Tsai J, Singer NV, West ML, Hanash A, Albert MH, Liu B, Toth M, van den Brink MRM. The central nervous system is a target of acute graft versus host disease. Blood. 2013; 121(10):1906-10.
  7. Holland AM, Zakrzewski JL, Tsai JJ, Hanash AM, Dudakov JA, Smith OM, West ML, Singer NV, Sun JC, van den Brink MRM. Extrathymic development of murine T cells after bone marrow transplantation. Journal of Clinical Investigation. 2012; 122: 4716-4726. PMCID: PMC3533530;
  8. Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne J, Papadopoulos EB, van den Brink MRM, Young J, Boulad F, Kernan N, O’Reilly RJ, Prockop S, Yahalom J, Heller G, Perales MA. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in 1st complete remission with a decreased risk of graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2013; 19(2):208-13.
  9. Perales MA, Goldberg JD, Yuan J, Koehne J, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, Devlin S, van den Brink MRM. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 2012; 120: 4882-4891. (commentary in Blood 2012; 120:4669-4770).
  10. van Heijst JWJ, Wasilewski GD, Lipuma LB, Ceberio I, van den Brink MRM, Perales MA, Pamer EG. Quantitative assessment of human T-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation. Nature Medicine. 2013; 19: 372–377.
  11. Taur Y, Xavier J, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci N, Viale A, Perales M, Jenq R, van den Brink M, Pamer EG. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clinical Infectious Diseases. 2012; 55: 905-914.
  12. Hanash AM, Dudakov JA, Hua G, O’Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MRM. IL-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft vs. host disease. Immunity. 2012; 37:339-350. (Previews in Immunity 2012; 37:196). PMCID:PMC3477611;
  13. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MRM, Perales M-A. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2013; 48:99-104.
  14. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh S, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG*, van den Brink MRM*. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.  *these authors contributed equally. Journal of Experimental Medicine. 2012; 209:903-911. (Research Highlight in Nature Reviews Immunology 2012; 12:399) PMCID: PMC3348096;
  15. Jenq RR, Curran M, Goldberg G, Liu C, Allison J, van den Brink M. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS ONE. 7(4):e35222. PMCID:PMC3320876;
  16. Dudakov JA, Hanash AM, Jenq RR, Young LF, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MRM. IL-22 drives endogenous thymic regeneration in mice. Science. 2012; 336:91-95. (Perspectives in Science 2012; 336:40; Leading Edge Select in Cell 2012; 149:729)
  17. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Vlierberghe PV, Dolgaley I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MRM, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab, O, Levine R. Prognostic and therapeutic relevance of integrated genetic profiling in AML. New England Journal of Medicine. 2012; 366:1079-89.
  18. Goldberg J, Chou J, Horwitz S, Feldstein J, Barker J, Boulad F, Castro-Malaspina H, Giralt S, Jakubowski A, Koehne G, van den Brink MRM, Young J, Zhang Z, Papadopoulos E, Perales M. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplantation. Leukemia & Lymphoma. 2012; 53:1124-9.
  19. Lu SX, Willis L, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith OM, Suh D, King C, Rao U, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan SM, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MRM. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. PLoS ONE; 2011;6(7): e21611. PMCID: PMC3130781
  20. Hanash AM, Kappel LW, Yim NL, Nejat RA, Goldberg GL, Smith OM, Rao UK, Dykstra L, Na IK, Holland AM, Dudakov JA, Liu C, Murphy GF, Leonard WJ, Heller G, van den Brink MRM. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood. 2011; 118:446-55. PMCID: PMC3138694
  21. Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, Perales MA, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN. Serious Infection Risk and Immune Recovery after Double-Unit Cord Blood Transplantation Without Antithymocyte Globulin. Biology of Blood and Marrow Transplantation. 2011; 17:1460-1471. PMCID: PMC3165093
  22. Ponce DM, Zheng J, Gonzales A, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O'Reilly RJ, Barker JN. Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2011; 17: 1316-1326. PMCID: PMC3156939
  23. Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Koehne G, Hsu K, Perales MA, Papanicolaou G, van den Brink MRM, O’Reilly RJ, Young JW, Papadopoulos EB. T-cell depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biology of Blood and Marrow Transplantation. 2011; 17: 1335-1342. PMCID: PMC3094599
  24. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, Viale A, Socci ND, van den Brink MR, Kamboj M, Pamer EG. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. Journal of Clinical Investigation. 2010; 120: 4332-4341. PMCID: PMC2993598
  25. Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, Wells DS, Heller G, Papadopoulos EB, Scaradavou A, Young JW, van den Brink MRM. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biology of Blood and Marrow Transplantation. 2010; 16:1541-1548.
  26. Lu SX, Na I, Terwey TH, Alpdogan O, Bautista JL, Smith OM, Suh D, Lin J, King C, Kochman A, Hubbard VM, Rao UK, Yim N, Liu C, Jenq R, Zakrzewski JL, Holland AM, Penack O, van den Brink MRM. Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease. The Journal of Immunology. 2010; 185:1912-19.
  27. Na IK, Markley JC, Tsai J, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao U, Stephan MT, Serganova I, Santos EB, Brentjens RJ, Blasberg RG, Sadelain M, van den Brink MRM. Concurrent visualization of trafficking, expansion and activation of T lymphocytes and T cell precursors in vivo. Blood. 2010; 116:18-25. PMCID:PMC3173994
  28. Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Lu TT, May C, Scheinberg DA, Gao DC, Mittal V, Benezra R, van den Brink MRM. Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor Growth. Journal of the National Cancer Institute. 2010; 102:894-908. PMCID: PMC2886094
  29. Perales MA, Jenq R, Jenna JD, Wilton AS, Lee SSE, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MRM, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O’Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age-adjusted international prognostic index in patients with advanced Non-Hodgkin Lymphoma after T-cell depleted allogeneic hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation. 2010; 45:1408-1416. PMID: 20062091
  30. Na IK, Lu SX, Yim N, Goldberg GL, Tsai J, Rao U, Smith OM, CG King, Suh D, Hirschhorn-Cymerman D, Palomba, ML, Penack O, Holland AM, Jenq RR, Ghosh A, Tran H, Merghoub T, Liu C, Sempowski G, Ventevogel M, Beauchemin N, van den Brink MRM. The cytolytic molecules Fas ligand and TRAIL are required for thymic graft-versus-host-disease. Journal of Clinical Investigation. 2010; 120:1,343-356. PMCID: PMC2798682
  31. Penack O, Smith OM, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Brandl K, van den Brink MRM. NOD2 regulates hematopoietic cell function during graft-versus-host disease. Journal of Experimental Medicine. 2009; 206:2101-2110. PMCID: PMC2757869
  32. Rotolo JA, Stancevic B, Lu SX, Zhang J, Suh D, King CG, Kappel LW, Murphy GF, Liu C, Fuks Z, van den Brink MRM, Kolesnick R. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood. 2009; 114:3693-3706. PMCID: PMC2766684
  33. Goldberg GL, King CG, Suh DY, Smith OM, Ajodan R, Samstein R, Dudakov J, Chidgey AP, Boyd RL, van den Brink MRM. Lutenizing hormone releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. Journal of Immunology. 2009; 182:5846-5854. PMCID: PMC2760441
  34. Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao U, Yim N, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MRM. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood. 2009; 113:1574-1580. PMCID: PMC2644085
  35. Kappel LW, Goldberg GL, King CG, Suh D, Smith OM, Ligh C, Holland A, Grubin J, Mark NM, Liu C, Iwakura Y, Heller G, van den Brink MRM. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009; 113:945-952. PMCID: PMC2630280
  36. Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, Gao GJ, Suh D, King C, Chow M, Smith OM, Hubbard VM, Bautista JL, Cabrera-Perez J, Zakrzewski JL, Kochman AA, Chow A, Altan-Bonnet G, van den Brink MRM. STAT-3 and ERK1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood. 2008; 112:5254-5258. PMCID: PMC2597618
  37. Pao M, Papadopoulos EB, Chou J, Heller G, Castro-Malaspina H, Jakubowski AA, Kernan NA, Perales MA, Prokop S, Scaradavou A, van den Brink MR, Young JW, O’Reilly RJ, Small TN. Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biology of Blood and Marrow Transplantation. 2008; 14:1022-1030.
  38. Alpdogan SO, Lu SX, Patel N, McGoldrick S, Suh D, Budak-Alpdogan T, Smith OM, Grubin J, King C, Goldberg G, Hubbard VM, Kochman AA, van den Brink MRM. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay post-transplant T cell reconstitution after allogeneic bone marrow transplantation. Blood. 2008; 112:4755-4764. PMCID: PMC2597141
  39. Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R. Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant’Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Liu C, van den Brink MRM. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature Biotechnology. 2008; 4:453-461. (commentary in Nature Reviews in Immunology. 2008; 8:321) PMCID: PMC2731996
  40. Kim TD, Terwey TH, Zakrzewski JL, Suh D, Kochman AA, Chen ME, King CG, Borsotti C, Grubin J, Smith OM, Heller G, Liu C, Murphy GF, Alpdogan O, van den Brink MRM. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood. 2008; 111:2929-2940. PMCID: PMC2254543
  41. Castro-Malaspina H, Jakubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O’Reilly RJ. Transplantation in remission improves the disease free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA identical siblings. Biology of Blood and Marrow Transplantation. 2008; 14:458-468.
  42. Jakubowski AA, Small TN, Young JW, Kernan NA, Perales MA, Castro-Malaspina H, Hsu K, Collins N, Chiu M, van den Brink M, O’Reilly RJ, Papadopoulos EB. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007; 110:4552-4559. PMCID: PMC2234775
  43. Chewning JH Castro-Malaspina H, Jakubowski A, Kernan N, Papadopoulos EB Small TN Heller G, Hsu K, Perales MA, van den Brink MRM, Young JW, Prockop SE, Collins N, O’Reilly RJ, Boulad F. Fludarabine-Based Conditioning Secures Engraftment of Secondary Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Primary Graft Failure. Biology of Blood and Marrow Transplantation. 2007; 13:1313-1323.
  44. Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Alpdogan O, van den Brink MRM. IFNg and FasL are required for graft-versus-tumor activity against renal cell carcinoma in the absence of graft-versus-host disease. Journal of Immunology. 2007; 179:1669-1680.
  45. Borsotti C, Franklin ARK, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MRM. Absence of donor T cell-derived soluble TNF decreases graft-versus-host-disease without impairing graft-versus-tumor activity. Blood. 2007; 110:783-786. PMCID: PMC1924485
  46. Goldberg GL, Alpdogan O, Sutherland JS, Muriglan SJ, Willis LM, Greenberg AS, Eng JM, van den Brink MRM*, Boyd RL*. Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation. Journal of Immunology. 2007; 178:7473-7484. *these authors contributed equally
  47. Meada T, Merghoub T, Hobbs RM, Dong L, Meada M, Zakrzewski J, van den Brink MRM, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, Pandolfi PP. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science. 2007; 316:860-866.
  48. Wingard JR, Leahigh AK, Confer D, Edwards J, Billups RL, van den Brink M, Keating A. Preparing for the Unthinkable: Emergency Preparedness for the Hematopoietic Cell Transplant Program. Biology of Blood and Marrow Transplantation. 2006; 12:1229-1238.
  49. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Cabrera-Perez J, Radhakrishnan R, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MRM. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nature Medicine. 2006; 12:1039-1047.
  50. Perales M-A, Diab A, Cohen AD, Huggins DW, Guevara-Patino JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G,  Wolchok JD, Houghton AN, van den Brink MRM. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. Journal of Immunology. 2006; 177:4159-4167.
  51. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Hubbard VM, Kochman AA, Lu SX, Miles RC, Sakaguchi S, Houghton AN, van den Brink MRM. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. Journal of Immunology. 2006; 176:6434-6442.
  52. Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, Alpdogan O, van den Brink M, Bertino JR, Blasberg RG, Banerjee D, Gelovani J. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplant. 2006; 15:75-82.
  53. Alpdogan O, Hubbard VM, Smith OM, Goldberg GL, Gray DH, Lu S, Kochman AA, Eng JM, Muriglan SJ, Boyd RL, van den Brink MRM. Keratinocyte growth factor (KGF) is required for post-natal thymic regeneration. Blood. 2006; 107:2453-2460. PMCID: PMC1895735
  54. Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MRM*, Scheinberg DA*. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 2006; 107:2045-2051. PMCID: PMC1895712 *these authors contributed equally
  55. Waldman E, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Lu SX, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MRM. Absence of the b7 integrin results in less graft-versus-host disease due to decreased homing of alloreactive T cells to the intestine. Blood. 2006; 107:1703-1711. PMCID: PMC1895413
  56. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu SX, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MRM. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005; 106:3322-3330. PMCID: PMC1895329
  57. Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MRM. Absence of inducible costimulator on alloreactive T cells reduces graft-versus-host disease and induces Th2 deviation. Blood. 2005; 106:3285-3292. PMCID: PMC1895338
  58. Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Tjoe KH, Hubbard VM, van den Brink MRM.  Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood. 2005; 105: 865-873.
  59. Muriglan SJ, Ramirez-Montagut T, Alpdogan O, van Huystee TW, Eng JM, Hubbard VM, Kochman AA, Tjoe KH, Riccardi C, Pandolfi PP, Sakaguchi S, Houghton AN, van den Brink MRM. GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-versus-Host Disease. Journal of Experimental Medicine. 2004; 200:149-157. PMCID: PMC2212013
  60. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ. Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biology of Bone Marrow Transplantation. 2004; 10:448-460.
  61. Sugerman PB, Faber S, Willis LM, Murphy GF, Pappo J, Silberstein D, van den Brink MRM. Kinetics of gene expression in murine cutaneous graft-versus-host disease. American Journal of Pathology. 2004; 164:2189-2202. PMCID: PMC1615752
  62. Perez LE, Alpdogan O, Shieh J, Wong D, Merzouk A, Salara H, O’Reilly RJ, van den Brink MRM*, Moore MAS*. Increased plasma levels of stromal derived factor-1 (SDF/CXCL12) enhance human thrombopoiesis and mobilizes human colony forming cells in NOD/SCID mice. Experimental Hematology. 2004; 32:300-307. *these authors contributed equally
  63. Petrovic A, Alpdogan O, Willis LM, Eng JF, Greenberg AS, Kappel BJ, Liu C, Murphy G, Heller G, van den Brink MRM. LPAM (a4ß7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal Graft-Versus-Host Disease. Blood. 2004; 103:1542-1547.
  64. Alpdogan O, Muriglan SJ, Eng J, Willis LM, Greenberg AS, van den Brink MRM. Interleukin-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. Journal of Clinical Investigation. 2003; 112:1095-1107. PMCID: PMC198519
  65. Alpdogan O, Schmaltz C, Muriglan SJ, Doubrovina E, Schiro R, Kappel BJ, Greenberg AS, Willis LM, Rotolo JA, O’Reilly RJ, van den Brink MRM. Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation. 2003; 75:1977-1983.
  66. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MRM. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003; 101:2440-2445.
  67. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon J, van den Brink MRM. T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine. 2002; 8:1433-1437.
  68. Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, van den Brink MRM, Small TN, Kernan NA, O’Reilly RJ, Ho DD, Young JW. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplants. Blood. 2002; 100:2235-2242.
  69. Pastores SM, Papadopoulos E, van den Brink MRM, Alicea M, and Halpern NA. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplantation. 2002; 30:131-134.
  70. Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA, Rich BE, van den Brink MRM. Administration of Interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host-disease. Blood. 2001; 98:2256-2265.
  71. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JLM, Burakoff SJ, van den Brink MRM. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host-disease and graft-versus-leukemia. Blood. 2001; 97:2886-2895.
  72. McDermott DF, Mier JW, Lawrence DP, van den Brink MRM, Clancy MA, Rubin KM, Atkins MB. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clinical Cancer Research. 2000; 6:2201-2208.
  73. Van den Brink MRM, Moore E, Horndasch KJ, Crawford JM, Murphy GF, Burakoff SJ. Fas ligand-deficient gld mice are more susceptible to graft-versus-host disease. Transplantation. 2000; 70:184-190.
  74. Van den Brink MRM, Moore E, Ferrara JLM, Burakoff SJ. Graft-versus-host disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation. 2000; 69:446-449.
  75. Van den Brink MRM, Moore E, Horndasch KJ, Crawford JM, Hoffman J, Murphy GF, Burakoff SJ. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. Journal of Immunology. 2000; 164:469-480.
  76. Pratt JC*, van den Brink MRM*, Igras VE, Walk SF, Ravichandran KS, Burakoff SJ. Requirement for Shc in T cell antigen receptor-mediated activation of a T cell hybridoma. Journal of Immunology. 1999; 163:2586-2591. PMID: 10452997 *shared first authorship
  77. Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MRM, Ferrara JLM. Interleukin-11 separates Graft-versus-Leukemia effect from Graft-versus-Host disease after allogeneic bone marrow transplantation. Journal of Clinical Investigation. 1999; 104:317-325.
  78. Van den Brink MRM, Kapeller R, Pratt JC, Chang JH, Burakoff SJ. 1999. The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells. Journal of Biological Chemistry. 1999; 274:11178-11185.
  79. Cooke KR, Krenger W, Hill G, Martin TR, Kobzik L, Brewer J, Simmons R, Crawford JM, van den Brink MRM, Ferrara, JLM. Host reactive donor T cells are associated with lung injury after experimental allogeneic BMT. Blood. 1998; 92:2571-2580.
  80. Van den Brink MRM, Dezube BJ. AIDS-related Kaposi’s sarcoma. Journal of Clinical Oncology. 1997; 15:1283-1284.
  81. Van den Brink MRM, French SW, Beck TP, Hronakes ML, Wren SM, Ildstad ST. Characterization of maturation and function of natural killer cells in xenogeneic (rat to mouse) bone marrow chimeras. Evidence that rat NK cells are present and functional in a xenogeneic environment. Transplantation. 1993; 55:355-361.
  82. Ildstad ST, Boggs SS, Vecchini F, Wren SM, Hronakes ML, Johnson PC, van den Brink MRM. Mixed xenogeneic chimeras (rat + mouse to mouse). Evidence of rat stem cell engraftment, strain-specific transplantation tolerance, and skin-specific antigens. Transplantation. 1992; 53:815-822.
  83. Van den Brink MRM, Herberman RB, Hiserodt JC. Generation of natural killer cells from Thy 1.1+ bone marrow precursor cells in the rat. Blood. 1991; 78:2392-2395.
  84. Francavilla A, Starzl TE, Barone M, Zeng Q, Porter KA, Zeevi A, Markus PM, van den Brink MRM, Todo S. Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK506. Hepatology. 1991; 14:140-143.
  85. Van den Brink MRM, Palomba MLAP, Basse PH, Hiserodt JC. In situ localization of 3.2.3+ natural killer cells in tissues from normal and tumor-bearing rats. Cancer Research. 1991; 51:4931-4936.
  86. Ildstad ST, Wren SM, Boggs SS, Hronakes ML, Vecchini F, van den Brink MRM. Cross-species bone marrow transplantation: Evidence for tolerance induction, stem cell engraftment, and maturation of T lymphocytes in a xenogeneic stromal environment (rat to mouse). Journal of Experimental Medicine. 1991; 174:467-478.
  87. Markus PM, van den Brink MRM, Luchs BA, Fung JJ, Starzl TE, Hiserodt JC. Effects of in vivo treatment with FK506 on natural killer (NK) cells in rats. Transplantation. 1991; 51:913-915.
  88. Van den Brink MRM, Boggs SS, Herberman RB, Hiserodt JC. The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. Journal of Experimental Medicine. 1990; 172:303-313.
  89. Van den Brink MRM, Hunt LE, Hiserodt JC. In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. Journal of Experimental Medicine. 1990; 171:197-210.
  90. Van den Brink MRM, Voogt PJ, Marijt WA, van Luxemburg-Heys SAP, van Rood JJ, Brand A. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood. 1989; 74:354-360.
  91. Sarneva M, Vujanovic NL, van den Brink MRM, Herberman RB, Hiserodt JC. Lymphokine-activated killer cells in rats: Generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells. Cellular Immunology. 1989; 118:448-457.
Visit PubMed for full listing of Marcel R.M. van den Brink journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.